Heart Test Laboratories (NASDAQ:HSCS) vs. Pathfinder Cell Therapy (OTCMKTS:PFND) Financial Comparison

Heart Test Laboratories (NASDAQ:HSCS) and Pathfinder Cell Therapy (OTCMKTS:PFND) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Institutional and Insider Ownership

17.2% of Heart Test Laboratories shares are held by institutional investors. 1.8% of Heart Test Laboratories shares are held by insiders. Comparatively, 15.1% of Pathfinder Cell Therapy shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Heart Test Laboratories and Pathfinder Cell Therapy, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heart Test Laboratories	0	0	2	0	3.00
Pathfinder Cell Therapy	0	0	0	0	0.00

Heart Test Laboratories presently has a consensus price target of $13.50, indicating a potential upside of 294.74%. Given Heart Test Laboratories’ stronger consensus rating and higher probable upside, analysts clearly believe Heart Test Laboratories is more favorable than Pathfinder Cell Therapy.

Earnings and Valuation

This table compares Heart Test Laboratories and Pathfinder Cell Therapy”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heart Test Laboratories	$14,700.00	212.41	-$6.61 million	($7.91)	-0.43
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A

Pathfinder Cell Therapy has lower revenue, but higher earnings than Heart Test Laboratories.

Profitability

This table compares Heart Test Laboratories and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Heart Test Laboratories	N/A	-144.12%	-94.48%
Pathfinder Cell Therapy	N/A	N/A	N/A

Summary

Heart Test Laboratories beats Pathfinder Cell Therapy on 5 of the 8 factors compared between the two stocks.

About Heart Test Laboratories

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.